R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature
<p>Abstract</p> <p>Purpose</p> <p>R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used successfully in the treatment of patients with symptomatic fol...
Main Authors: | Vijay Patel, Siddhartha Ganguly |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-03-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://www.jhoonline.org/content/2/1/14 |
Similar Items
-
An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
by: Yaxiao Lu, et al.
Published: (2021-07-01) -
Complete Regression of Primary Cardiac Lymphoma With Dose-Attenuated R-CVP Chemotherapeutic Regimen
by: Amit K.J. Mandal, MBBS, et al.
Published: (2019-10-01) -
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
by: Aguiar-Bujanda D, et al.
Published: (2015-10-01) -
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
by: Carsten Hirt, et al.
Published: (2021-07-01) -
Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
by: Yoshinori Wakasugi, et al.
Published: (2019-11-01)